Advanced Search

Study Preview



Study Title and Description

β2-1 Fructan supplementation alters host immune responses in a manner consistent with increased exposure to microbial components: results from a double-blinded, randomised, cross-over study in healthy adults.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title β2-1 Fructan supplementation alters host immune responses in a manner consistent with increased exposure to microbial components: results from a double-blinded, randomised, cross-over study in healthy adults.
Author Clarke ST., Green-Johnson JM., Brooks SP., Ramdath DD., Bercik P., Avila C., Inglis GD., Green J., Yanke LJ., Selinger LB., Kalmokoff M.
Country 1Applied Bioscience Graduate Program, Faculty of Science,University of Ontario Institute of Technology,Oshawa,ON,Canada L1H 7K4.
Year 2016
Numbers Pubmed ID: 26987626

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2016
  • Comments Comments (
    0
    ) |
country Canada
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol Food partially provided (partial metabolic study)
  • Comments Comments (
    0
    ) |
sampsize 30
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol 1
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 28.1
  • Comments Comments (
    0
    ) |
age_range 18-50
  • Comments Comments (
    0
    ) |
bmi_mean 24.2
  • Comments Comments (
    0
    ) |
bmi_range 18-30
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~43
  • Comments Comments (
    0
    ) |
ftype1 Combination/Mixture
  • Comments Comments (
    0
    ) |
descrip1_1 inulin
  • Comments Comments (
    0
    ) |
descrip1_2 short-chain oligosaccharides
  • Comments Comments (
    0
    ) |
dose1_1 7.5
  • Comments Comments (
    0
    ) |
dose1_2 7.5
  • Comments Comments (
    0
    ) |
duration1 28 days
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 placebo
  • Comments Comments (
    0
    ) |
cdose1 15g
  • Comments Comments (
    0
    ) |
cduration1 28 days
  • Comments Comments (
    0
    ) |
cadmin1 Powder
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.